X

The ASCO Post

The ASCO Post
Outcomes With Ribociclib Across Intrinsic Subtypes of HR-Positive, HER2-Negative Breast Cancer

Dr Aleix Prat and colleagues find consistent progression-free survival benefits with the combination of ribociclib plus endocrine therapy vs placebo plus endocrine therapy across all intrinsic subt

The ASCO Post
04/08/2021
Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer

The combination of lenvatinib, a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3 kinases, and pembrolizumab significantly improved multiple outcomes compared with standard single-agent CT in...

The ASCO Post
04/10/2021
Diet and Exercise Intervention May Increase Efficacy of Chemotherapy in Pediatric Patients With Leukemia

Research published by Orgel et al shows that restricting calories, reducing fat and sugar intake, and increasing physical activity may boost the effectiveness of chemotherapy for older children and

The ASCO Post
04/07/2021
Germline BRCA1/2 and Other Predisposition Genes in Patients With Metastatic Breast Cancer: Prevalence and Association With Prognosis

Fasching and colleagues identify the prevalence of germline mutations in BRCA1/2 and other breast cancer risk genes in patients with metastatic disease and found similar prognosis with pre

The ASCO Post
04/06/2021
Overall Survival With Olaparib vs Placebo Maintenance in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and BRCA1/2 Mutation

The phase III SOLO2/ENGOT-Ov21 trial has shown a large numeric but statistically nonsignificant improvement in the secondary endpoint of overall survival with olaparib tablet maintenance therapy vs

The ASCO Post
04/06/2021
Tipifarnib for Patients With Advanced HRAS-Mutant Head and Neck Cancer and High Variant Allele Frequency

In a phase II trial, Ho et al finds that tipifarnib produces a high response rate among patients with recurrent or metastatic HNSCC with HRAS mutations and high variant allele frequency.

The ASCO Post
04/05/2021
Medicaid Expansion Is Associated With Earlier Diagnosis of Gastric Cancer, Improved Survival

Medicaid expansion caused a decrease in uninsured patients and led to an earlier diagnosis of gastric cancer with an associated increase in 1-year survival.

The ASCO Post
04/02/2021
ASTRO Survey Explores Effect of COVID-19 on Radiation Oncology

Radiation oncologists report new patients are arriving for treatment with more advanced-stage disease than before the COVID-19 pandemic, according to a new survey conducted by the ASTRO this winter

The ASCO Post
04/02/2021
Next Up in NSCLC: Antibody-Drug Conjugates

Antibody-drug conjugates directed against HER2, HER3, and trophoblast cell-surface antigen 2 are showing encouraging antitumor activity in advanced non–small cell lung cancer.

The ASCO Post
03/25/2021
LuPSMA Outperforms Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer in Phase II Trial

Following disease progression on docetaxel, PSMA-targeted radionuclide therapy reduces the risk of disease progression or death by 37% vs cabazitaxel in men with mCRPC...

The ASCO Post
03/25/2021
Subscribe to The ASCO Post

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39